Author

K. P. Guillen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

B. E. Welm· 3 shared C.-H. Yang· 3 shared E. Cortes-Sanchez· 2 shared J. Gertz· 2 shared J. M. Vahrenkamp· 2 shared K. E. Varley· 2 shared A. Almomen· 1 shared A. C. Beck· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. E. Welm

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology

PELP1/SRC-3-dependent regulation of metabolic kinases drives therapy resistant ER+ breast cancer

T. H. Truong, E. A. Benner, K. M. Hagen, N. A. Temiz, C. Perez Kerkvliet, Y. Wang, E. Cortes-Sanchez, C.-H. Yang, T. Pengo, K. P. Guillen, B. W. Welm, S. Telang, C. A. Lange, J. H. Ostrander

This study identifies PELP1/SRC-3-dependent regulation of metabolic kinases as a driver of therapy-resistant ER+ breast cancer and shows that targeting PFKFBs can block tumorsphere formation in resistant models.

bioRxiv · Aug 7, 2020Cancer Biology

STAT3 and GR cooperate to drive basal-like triple negative breast cancer gene expression and proliferation.

M. E. Conway, J. M. McDaniel, J. M. Graham, K. P. Guillen, P. G. Oliver, S. L. Parker, P. Yue, J. Turkson, D. J. Buchsbaum, B. E. Welm, R. M. Myers, K. E. Varley

This study identifies GR and STAT3 as cooperative drivers of basal-like triple negative breast cancer gene expression and shows that their inhibition synergistically reduces cell proliferation.

bioRxiv · Aug 9, 2019Cancer Biology

Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor α in endometrial cancer

J. M. Vahrenkamp, C.-H. Yang, A. C. Rodriguez, A. Almomen, K. Berrett, A. N. Trujillo, K. P. Guillen, B. E. Welm, E. A. Jarboe, M. M. Janat-Amsbury, J. Gertz

The paper investigates the interaction between glucocorticoid receptor (GR) and estrogen receptor α (ER) in endometrial cancer, finding that GR expression correlates with poor prognosis and that their combined activity alters gene expression and genomic binding.

bioRxiv · Mar 7, 2018Cancer Biology